Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Jun 2026
NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunoth
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
11:13am, Wednesday, 20'th May 2026
Candel Therapeutics NASDAQ: CADL Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer dat
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
10:55am, Tuesday, 19'th May 2026
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
08:05am, Thursday, 14'th May 2026
NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe
Candel Therapeutics to Present at Upcoming Investor Conferences
08:05am, Wednesday, 13'th May 2026
NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot
NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunothe
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st May 2026
NEEDHAM, Mass. , May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Fed holds rates, but rare split exposes deepening divide
11:14am, Wednesday, 29'th Apr 2026
The US Federal Reserve left interest rates unchanged on Wednesday, in line with market expectations, but policymakers showed an unusual split over the path...
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch
08:39am, Wednesday, 29'th Apr 2026
Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a g
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026
Regeneron shares slide despite Q1 beat
06:12am, Wednesday, 29'th Apr 2026
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares fell more than 5.5% on Wednesday morning even as the drugmaker reported better-than-expected...
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch
04:36am, Wednesday, 29'th Apr 2026
Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a...
